[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-363169-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-363169-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","apr-246-drives-ros-dependent-ferroptosis-and-apoptosis-and-enhances-antipd-1-efficacy-in-bladder-cancer","APR-246 drives ROS-dependent ferroptosis and apoptosis and enhances anti–PD-1 efficacy in bladder cancer","","APR-246 (eprenetapopt) preferentially reduces viability in TP53-mutant bladder cancer cell lines, with activity partly dependent on mutant p53. Mechanistically, it induces pronounced reactive oxygen species accumulation and activates ferroptosis and apoptosis while reactivating p53-linked transcriptional programs. RNA sequencing and validation identify increased secretion of T cell–recruiting chemokines CCL5 and CXCL10. In bladder tumor models, APR-246 suppresses growth and enriches CD8+ CD4+ T cells and NK cells, and it augments anti–PD-1 efficacy via immune remodeling.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/apr-246-drives-ros-dependent-ferroptosis-and-apoptosis-and-enhances-antipd-1-efficacy-in-bladder-cancer/363169/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/apr-246-drives-ros-dependent-ferroptosis-and-apoptosis-and-enhances-antipd-1-efficacy-in-bladder-cancer/363169.png","ImageObject",300,407,{"name":42,"@type":43},"Cart","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-31","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",5,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How does APR-246 affect TP53-mutant bladder cancer cells?","Question",{"text":63,"@type":64},"APR-246 preferentially reduces viability in TP53-mutant bladder cancer cell lines, and its effect appears partially dependent on mutant p53.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What mechanisms connect APR-246 treatment to ferroptosis and apoptosis?",{"text":68,"@type":64},"APR-246 induces strong reactive oxygen species accumulation and engages ferroptosis and apoptosis in parallel, together with reactivation of p53-associated transcriptional programs.",{"name":70,"@type":61,"acceptedAnswer":71},"How does APR-246 influence anti–PD-1 therapy outcomes?",{"text":72,"@type":64},"In bladder tumor models, APR-246 augments anti–PD-1 efficacy and increases effector immune infiltration, supporting a rationale for combining mutant p53 targeting with PD-1 blockade.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},363169,1790698463,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,100,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":55,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":108,"preview_page_count":33,"preview_urls":145},18829141979164,"https://eur-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nAPR-246 drives ROS-dependent ferroptosis and apoptosis and enhances anti–PD-1 efficacy in bladder cancer  \nChi Zhang1,2,5, Senming Cao1,2,5, Guineng Zeng1,5, Yuhao Dong2,3,4, Hongzhao Li1,2, Xin Ma1,2, Xu Zhang1,2􀀍, Zhi Li1,2􀀍 & Yan Huang1,2,3􀀍  \nTP53 is frequently mutated in bladder cancer and is associated with aggressive disease, yet actionable strategies that also improve responses to immune checkpoint blockade remain limited. Here we show that APR-246 (eprenetapopt), a mutant p53–reactivating agent, preferentially reduces viability in TP53-mutant bladder cancer cell lines and that its activity appears to be partially dependent on mutant p53. Mechanistically, APR-246 induces pronounced reactive oxygen species accumulation and engages ferroptosis and apoptosis in parallel, accompanied by reactivation of p53-associated transcriptional programmes. RNA sequencing and orthogonal validation further reveal increased expression and secretion oftheT cell–recruiting chemokines CCL5 and CXCL10 . In syngeneic subcutaneous and orthotopic bladder tumour models, APR-246 suppresses tumour growth and is associated with increased infiltration of CD8⁺ and CD4⁺ T cells and natural killer cells, though limited by sample size in animal models; This antitumour effect is attenuated in immunodeficient hosts. Notably, APR-  \n246 augments the efficacy of anti–PD-1 therapy and further enriches effector immune infiltration. Together, these findings link mutant p53 targeting and redox-driven cell death to immune remodelling, providing a mechanistic rationale for combining APR-246 with PD-1 blockade in bladder cancer.  \nKeywords Bladder cancer, APR-246, TP53 mutation, Tumour immune microenvironment, PD-1 blockade  \nBladder cancer is among the most common malignancies of the urinary tract, with initiation and progression driven by dysregulated molecular signalling networks1. Molecular epidemiological studies identify TP53 as oneof the most frequently mutated somatic genes in bladder cancer; approximately 50% of patients harbour TP53 alterations, predominantly missense mutations2–4. TP53 orchestrates key programmes governing DNA damage responses, cell-cycle arrest, apoptosis and senescence5. TP53 mutation disables tumour-suppressive functions and may confer gain-of-function activities that promote proliferation, invasion and therapeutic resistance6. Clinicopathological evidence further indicates a higher prevalence of mutant p53 in muscle-invasive bladder cancer than in non–muscle-invasive disease, supporting an association between p53 aberrations, tumour progression and aggressive phenotypes7. Restoring mutant p53 activity has therefore emerged as a promising avenue for precision therapy in bladder cancer.  \nBladder cancer has long been regarded as a partially immunogenic tumour8. Immunomodulatory approaches constitute standard care in non–muscle-invasive bladder cancer, and immune checkpoint blockade can induce durable responses in a subset of patients with advanced disease9, 10. Yet the overall benefit remains limited at the population level. Primary refractoriness and acquired resistance are common, shaped by an immunosuppressive tumour microenvironment and tumour-intrinsic variation in stress responses and cell-death programmes11. Combination strategies that couple direct tumour killing with immune microenvironment remodelling therefore represent a clear unmet clinical need.  \nAPR-246 (eprenetapopt) is among the most extensively studied small molecules for reactivating mutant p5312–14. Its active metabolite forms reversible adducts with key cysteine residues in mutant p53, stabilising its conformation and partially restoring wild-type–like transcriptional activity, thereby re-engaging canonical  \n1School of medicine, Nankai University, Tianjin 300071, China. 2Department of Urology, Chinese PLA General Hospital, Beijing 100039, China. 3Department of Urology Laboratory, Chi","cbCaipJq1IsOIX1W","https://ap.wps.com/l/cbCaipJq1IsOIX1W","pdf",2587035,16,"English","# Background\n## TP53 alterations and bladder cancer progression\n## Immunotherapy and the need for rational combinations\n# Mechanistic rationale\n## APR-246 as a mutant p53 reactivator\n## Redox stress, ROS, and ferroptosis\n## Ferroptosis links to anti-tumor immunity\n# Study findings\n## Effects on cancer cell viability and death pathways\n## Chemokine induction and immune cell recruitment\n## Tumor control and synergy with anti–PD-1","[{\"question\":\"How does APR-246 affect TP53-mutant bladder cancer cells?\",\"answer\":\"APR-246 preferentially reduces viability in TP53-mutant bladder cancer cell lines, and its effect appears partially dependent on mutant p53.\"},{\"question\":\"What mechanisms connect APR-246 treatment to ferroptosis and apoptosis?\",\"answer\":\"APR-246 induces strong reactive oxygen species accumulation and engages ferroptosis and apoptosis in parallel, together with reactivation of p53-associated transcriptional programs.\"},{\"question\":\"How does APR-246 influence anti–PD-1 therapy outcomes?\",\"answer\":\"In bladder tumor models, APR-246 augments anti–PD-1 efficacy and increases effector immune infiltration, supporting a rationale for combining mutant p53 targeting with PD-1 blockade.\"}]","APR-246 drives ROS-dependent ferroptosis and apoptosis and enhances anti–PD-1 efficacy in bladder cancer | PDF",1790150252,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3b328557ed8b3b9d5c20540439ddd180.webp",983,1291,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/400ae030ecc8626abf23d024b1149131.webp",982,1290,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5a5118e8bc67b9a7591a12d2797c0e05.webp",981,1289,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c25030b3786b59e432a53aa227f884db.webp",980,1287]